CAR-T therapy shows durable survival in hard-to-treat lymphoma patients

A new study tracking long-term outcomes for lisocabtagene maraleucel in second-line large B-cell lymphoma demonstrates sustained clinical benefit in patients who have failed initial treatment. The finding could reshape treatment sequencing and expand the market for cell therapies in a disease where options have historically been limited.

Originaltitel: Long-term survival with lisocabtagene maraleucel in second-line large B-cell lymphoma from TRANSFORM